129 related articles for article (PubMed ID: 34589914)
1. Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC.
Toyozawa R; Haratake N; Toyokawa G; Matsubara T; Takamori S; Miura N; Yamaguchi M; Takenoyama M; Seto T
JTO Clin Res Rep; 2020 Mar; 1(1):100012. PubMed ID: 34589914
[TBL] [Abstract][Full Text] [Related]
2. A Case of Immune-Related Aseptic Meningitis during Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma.
Kawanaka H; Tajiri K; Muraishi N; Murayama A; Nukui T; Yasuda I
Case Rep Gastroenterol; 2024; 18(1):8-13. PubMed ID: 38188593
[TBL] [Abstract][Full Text] [Related]
3. Immune-related aseptic meningitis diagnosed by Cube FLAIR on enhanced magnetic resonance imaging for a lung cancer patient administered atezolizumab: A case report.
Kuroda R; Nakagawa H; Uchida Y; Narumiya K; Tsunoda Y; Yamaguchi M; Oki T; Hiratsuka S; Nagatani Y; Nakano Y
Respirol Case Rep; 2023 Feb; 11(2):e01076. PubMed ID: 36605536
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report.
Yamaguchi Y; Nagasawa H; Katagiri Y; Wada M
J Med Case Rep; 2020 Jul; 14(1):88. PubMed ID: 32620173
[TBL] [Abstract][Full Text] [Related]
5. Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review.
Ogawa K; Kaneda H; Kawamoto T; Tani Y; Izumi M; Matsumoto Y; Sawa K; Suzumura T; Watanabe T; Mitsuoka S; Asai K; Kawaguchi T
Invest New Drugs; 2020 Dec; 38(6):1901-1905. PubMed ID: 32399862
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: A case report and literature review of aseptic meningitis as an immune-related adverse event.
Inui G; Funaki Y; Makino H; Touge H; Arai K; Kuroda K; Hirayama Y; Kato R; Nonaka T; Yamane K; Teruya Y; Sueda Y; Sakamoto T; Yamaguchi K; Kodani M; Kawase S; Umekita Y; Horie Y; Nosaka K; Yamasaki A
Mol Clin Oncol; 2022 Jul; 17(1):120. PubMed ID: 35747596
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review.
Thouvenin L; Olivier T; Banna G; Addeo A; Friedlaender A
Ther Adv Drug Saf; 2021; 12():20420986211004745. PubMed ID: 33854755
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
9. A Case Report of Hemophagocytic Lymphohistiocytosis and Meningitis Due to Atezolizumab Treatment for Lung Adenocarcinoma.
Ota H; Munechika M; Tobino K; Uchida K; Muarakami Y
Cureus; 2024 Apr; 16(4):e58253. PubMed ID: 38745801
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer.
Ramagopalan S; Gupta A; Arora P; Thorlund K; Ray J; Subbiah V
JAMA Netw Open; 2021 Nov; 4(11):e2134299. PubMed ID: 34767024
[TBL] [Abstract][Full Text] [Related]
11. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.
Bordoni R; Ciardiello F; von Pawel J; Cortinovis D; Karagiannis T; Ballinger M; Sandler A; Yu W; He P; Matheny C; Felizzi F; Rittmeyer A
Clin Lung Cancer; 2018 Sep; 19(5):441-449.e4. PubMed ID: 30017645
[TBL] [Abstract][Full Text] [Related]
12. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
[TBL] [Abstract][Full Text] [Related]
13. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
Fehrenbacher L; von Pawel J; Park K; Rittmeyer A; Gandara DR; Ponce Aix S; Han JY; Gadgeel SM; Hida T; Cortinovis DL; Cobo M; Kowalski DM; De Marinis F; Gandhi M; Danner B; Matheny C; Kowanetz M; He P; Felizzi F; Patel H; Sandler A; Ballinger M; Barlesi F
J Thorac Oncol; 2018 Aug; 13(8):1156-1170. PubMed ID: 29777823
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Rittmeyer A; Barlesi F; Waterkamp D; Park K; Ciardiello F; von Pawel J; Gadgeel SM; Hida T; Kowalski DM; Dols MC; Cortinovis DL; Leach J; Polikoff J; Barrios C; Kabbinavar F; Frontera OA; De Marinis F; Turna H; Lee JS; Ballinger M; Kowanetz M; He P; Chen DS; Sandler A; Gandara DR;
Lancet; 2017 Jan; 389(10066):255-265. PubMed ID: 27979383
[TBL] [Abstract][Full Text] [Related]
15. New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
Seetharamu N; Preeshagul IR; Sullivan KM
Lung Cancer (Auckl); 2017; 8():67-78. PubMed ID: 28761384
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Morphological Characteristics of Anti-Programmed Death Ligand 1-Associated Retinopathy: Expanding the Spectrum of Acute Macular Neuroretinopathy.
Ramtohul P; Freund KB
Ophthalmol Retina; 2020 Apr; 4(4):446-450. PubMed ID: 31926948
[TBL] [Abstract][Full Text] [Related]
17. A Case of Anti-CRMP5 Paraneoplastic Neurological Syndrome Induced by Atezolizumab for Small Cell Lung Cancer.
Tatsumi S; Uryu K; Iwasaki S; Harada H
Intern Med; 2020 Aug; ():. PubMed ID: 32788536
[TBL] [Abstract][Full Text] [Related]
18. Prospects and progress of atezolizumab in non-small cell lung cancer.
Vansteenkiste J; Wauters E; Park K; Rittmeyer A; Sandler A; Spira A
Expert Opin Biol Ther; 2017 Jun; 17(6):781-789. PubMed ID: 28335643
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.
von Pawel J; Bordoni R; Satouchi M; Fehrenbacher L; Cobo M; Han JY; Hida T; Moro-Sibilot D; Conkling P; Gandara DR; Rittmeyer A; Gandhi M; Yu W; Matheny C; Patel H; Sandler A; Ballinger M; Kowanetz M; Park K
Eur J Cancer; 2019 Jan; 107():124-132. PubMed ID: 30562710
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab-induced bilateral anterior uveitis: A case report.
Mito T; Takeda S; Motono N; Sasaki H
Am J Ophthalmol Case Rep; 2021 Dec; 24():101205. PubMed ID: 34585023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
